Latest Ratios: P/E Ratio 47.5x · EV/EBITDA 30.4x · ROE 8.6%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $994M | $849M | $420M | $331M | $707M | $1.8B | $978M | — | — |
| Enterprise Value | $1.8B | $1.4B | $1.1B | $744M | $656M | $1.1B | $2.1B | $1.3B | — | — |
| P/E Ratio → | 47.51 | 33.51 | 37.35 | 31.64 | 49.91 | 329.24 | 111.65 | 384.53 | — | — |
| P/S Ratio | 1.46 | 1.05 | 1.22 | 0.77 | 0.70 | 1.61 | 4.49 | 2.89 | — | — |
| P/B Ratio | 3.77 | 2.66 | 2.72 | 2.89 | 2.64 | 6.19 | 17.35 | 13.76 | — | — |
| P/FCF | 52.77 | 37.81 | 28.00 | 16.82 | — | — | 40.86 | 344.51 | — | — |
| P/OCF | 28.73 | 20.59 | 21.59 | 12.70 | 36.61 | — | 34.96 | 102.41 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.51 | 1.58 | 1.37 | 1.39 | 2.40 | 5.30 | 3.88 | — | — |
| EV / EBITDA | 30.43 | 23.87 | 24.81 | 24.55 | 37.17 | 111.54 | 87.91 | 138.49 | — | — |
| EV / EBIT | 35.49 | 27.34 | 28.64 | 29.16 | 51.59 | 226.35 | 108.35 | 231.55 | — | — |
| EV / FCF | — | 54.39 | 36.21 | 29.77 | — | — | 48.29 | 462.28 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 12.9% | 12.9% | 13.5% | 12.3% | 12.4% | 11.1% | 14.0% | 13.2% | 14.8% | 12.9% |
| Operating Margin | 5.4% | 5.4% | 5.5% | 4.6% | 2.7% | 1.1% | 4.8% | 1.7% | 7.2% | 6.1% |
| Net Profit Margin | 3.1% | 3.1% | 3.2% | 2.5% | 1.4% | 0.6% | 4.0% | 0.8% | 5.5% | 3.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 8.6% | 8.6% | 9.9% | 9.9% | 5.5% | 2.5% | 18.3% | 3.7% | 25.1% | 16.5% |
| ROA | 3.6% | 3.6% | 3.7% | 2.5% | 1.3% | 0.5% | 3.3% | 0.9% | 16.8% | 11.2% |
| ROIC | 5.6% | 5.6% | 5.6% | 4.1% | 2.1% | 0.8% | 3.4% | 1.8% | 24.7% | 19.3% |
| ROCE | 7.3% | 7.3% | 7.3% | 5.5% | 2.8% | 1.1% | 4.6% | 2.4% | 31.6% | 24.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.21 | 1.21 | 0.88 | 2.27 | 2.60 | 3.11 | 3.15 | 4.71 | — | — |
| Debt / EBITDA | 7.56 | 7.56 | 6.17 | 10.88 | 18.51 | 37.48 | 13.52 | 35.32 | — | — |
| Net Debt / Equity | — | 1.17 | 0.80 | 2.22 | 2.58 | 3.06 | 3.15 | 4.70 | -0.00 | -0.00 |
| Net Debt / EBITDA | 7.28 | 7.28 | 5.63 | 10.68 | 18.40 | 36.93 | 13.52 | 35.28 | -0.00 | -0.00 |
| Debt / FCF | — | 16.59 | 8.21 | 12.95 | — | — | 7.43 | 117.77 | -0.00 | -0.00 |
| Interest Coverage | 7.83 | 7.83 | 5.51 | 4.31 | 3.33 | 2.41 | 15.45 | 13.83 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.14 | 1.14 | 1.21 | 1.12 | 1.05 | 1.06 | 0.67 | 0.76 | 0.99 | 1.02 |
| Quick Ratio | 1.14 | 1.14 | 1.21 | 1.12 | 1.05 | 1.06 | 0.67 | 0.76 | 0.99 | 1.02 |
| Cash Ratio | 0.12 | 0.12 | 0.24 | 0.08 | 0.03 | 0.07 | 0.00 | 0.01 | 0.00 | 0.00 |
| Asset Turnover | — | 0.98 | 1.02 | 1.01 | 0.92 | 0.83 | 0.77 | 0.76 | 2.91 | 2.84 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 47.41 | 42.68 | 40.94 | 41.20 | 44.78 | 44.09 | 34.70 | 31.22 | 32.35 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 1.2% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | 455.6% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.1% | 3.0% | 2.7% | 3.2% | 2.0% | 0.3% | 0.9% | 0.3% | — | — |
| FCF Yield | 1.9% | 2.6% | 3.6% | 5.9% | — | — | 2.4% | 0.3% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.5% | — | — |
| Shares Outstanding | — | $35M | $32M | $30M | $30M | $31M | $30M | $30M | $28M | $28M |
Regulatory reimbursement rate volatility
Based on current market data, PNTG trades at a TTM P/E of 42.75, which, when compared to the broader healthcare services sector, suggests investors are pricing in significant future earnings expansion rather than current profitability, as evidenced by the elevated PEG ratio of 4.25.
The current valuation appears to bake in a high degree of confidence in the company's decentralized acquisition model. Investors should monitor whether this premium is sustainable if the pace of inorganic growth slows or if the Senior Living segment fails to achieve the anticipated margin recovery.
As reported in recent financial statements, PNTG's ROIC has remained consistently low, fluctuating between 1.2% and 1.9% over the last ten quarters, which indicates that the company is currently struggling to generate meaningful returns on the capital deployed for its aggressive acquisition strategy.
The persistent gap between the cost of capital and these low returns suggests that the integration of acquired agencies is not yet yielding the expected synergies. This trend warrants further investigation into whether the decentralized model is creating operational friction that offsets the benefits of scale.
According to quarterly filings, the company's DSO has hovered between 35 and 41 days, reflecting the inherent challenges of managing healthcare reimbursement cycles, while the lack of consistent CCC data suggests that operational efficiency is secondary to the company's primary focus on rapid inorganic expansion.
The variability in cash conversion cycles implies that the company's working capital position is highly sensitive to payer behavior and integration timing. Investors should be cautious, as any deterioration in collection efficiency could quickly strain the company's liquidity given its thin current ratio.
Based on the company's reported figures, the debt-to-equity ratio has improved from a peak of 2.27 in 2023Q4 to 1.15 in 2026Q1, signaling that management is successfully prioritizing balance sheet health while continuing to fund its acquisition-heavy growth strategy through more disciplined capital allocation.
While the reduction in leverage is a positive development, the interest coverage ratio remains volatile, ranging from 3.77 to 14.23. This suggests that while the debt burden is becoming more manageable, the company remains vulnerable to interest rate fluctuations and potential shifts in operating cash flow.
The P/E ratio is frequently misapplied to PNTG, as it obscures the significant impact of non-cash charges and acquisition-related integration costs that temporarily depress net income, making the company appear more expensive than its underlying cash-generating potential might otherwise suggest to a fundamental analyst.
Investors should instead focus on EV/EBITDA or cash-flow-based metrics to better capture the operational performance of the decentralized business units. Relying solely on P/E ignores the 'embedded call option' nature of the Senior Living assets and the potential for margin expansion as these units mature.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PNTG stock.
The Pennant Group, Inc.'s current P/E ratio is 47.5x. The historical average is 52.8x. This places it at the 60th percentile of its historical range.
The Pennant Group, Inc.'s current EV/EBITDA is 30.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 39.7x.
The Pennant Group, Inc.'s return on equity (ROE) is 8.6%. The historical average is 11.1%.
Based on historical data, The Pennant Group, Inc. is trading at a P/E of 47.5x. This is at the 60th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
The Pennant Group, Inc. has 12.9% gross margin and 5.4% operating margin.
The Pennant Group, Inc.'s Debt/EBITDA ratio is 7.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.